Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT04879563

PHASE2

Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project

Sponsor: Region Örebro County

View on ClinicalTrials.gov

Summary

ASCAPE (Artificial intelligence Supporting CAncer Patients across Europe) is a collaborative research project involving 15 partners from 7 countries, including academic medical centers, SMEs (small and medium-sized enterprises), research centers and universities, aiming to leverage the recent advances in Big Data and AI (Artificial Intelligence) to support cancer patients' Quality of Life (QoL) and health status. Specifically, ASCAPE aims to provide personalized- and AI-based predictions for QoL issues in breast- and prostate cancer patients as well as suggest potential interventions to their physicians. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875351.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

500

Start Date

2021-02-01

Completion Date

2025-08-30

Last Updated

2024-11-19

Healthy Volunteers

Conditions

Breast Cancer Prostate Cancer Quality of Life Survivorship Toxicity

Interventions

OTHER

ASCAPE-based follow-up strategy

Follow-up through ASCAPE platform including AI-based predictions for health-related QoL issues and suggestions for personalized interventions depending on the type of QoL issue that needs to be tackled. The ASCAPE-based follow-up strategy includes follow-up through validated QoL questionnaires, wearables for capturing active monitoring data, and mobile apps for answering the questionnaires and capturing potential health-related issues.

The patient selection process varies among the different study sites. Three Hospitals (Sismanogleio General Hospital Athens (SGHA), Örebro University Hospital (ÖUH), Uppsala University Hospital (UUH)) will include patients with newly diagnosed breast- (ÖUH, UUH) or prostate cancer (SGHA, ÖUH) who are eligible for curative treatment with surgery (breast cancer in ÖUH and UUH; prostate cancer in NKUA) or radiotherapy (prostate cancer; ÖUH). One Hospital (Barcelona) will include breast cancer survivors (at least 12 months after surgery or chemotherapy) with follow-up through the Hospital. Finally, CareAcross will include patients with breast- or prostate cancer through its online platform for patients seeking for the CareAcross services. Inclusion Criteria (breast cancer; ORB and Uppsala): * breast cancer diagnosis * no clinical evidence of metastatic disease * able for curative treatment with surgery with or without oncological treatment. Inclusion Criteria (breast cancer; Barcelona) * prior early breast cancer who are at follow-up with at least 12 months after surgery or chemotherapy (whichever occurred last). Inclusion Criteria (breast cancer; CareAcross) * breast cancer diagnosis (as per self-reported) irrespective of stage and treatment. Inclusion Criteria (prostate cancer; SGHA and ORB) * proostate cancer diagnosis * no clinical evidence of metastatic disease * able for curative treatment with surgery with or without oncological treatment (SGHA) or radiotherapy (with or without prior surgery) irrespectively the type of radiotherapy (external radiotherapy, brachytherapy, or combination). Inclusion Criteria (prostate cancer; CareAcross) * prostate cancer diagnosis (as per self-reported) irrespective of stage and treatment. Exclusion Criteria (common in all study sites): * inability to give informed consent * inability / no access to smartphones, applications or internet services * patients with known medical history of allergy to the wearable material.

Locations (5)

Urology Department, Sismanogleio General Hospital

Athens, Greece

Oncology Department, Hospital Clínic de Barcelona

Barcelona, Spain

Department of Oncology, Örebro University Hospital

Örebro, Sweden

Department of Oncology, University Hospital of Uppsala

Uppsala, Sweden

CareAcross

London, United Kingdom